Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C

doi:10.4254/wjh.v9.i5.252

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8127)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

401

WORD

254

HTML

2995

Figures (1-3)

274

Tables (1-6)

265

Sum=4189

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

475

Download

1119

Sum=1594

Publishing Process of This Article

Item

Count

Browse

879

Download

1465

Sum=2344

Feb 18, 2017 (publication date) through Feb 5, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Feb 18, 2017; 9(5): 252-262
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.252

Table 1 Patient characteristics by age (telaprevir)

Factors (median, range)	Patients aged < 66	Patients aged ≥ 66	P value
n	78	34
Gender, n (male/female)	41/37	20/14	0.68
Age (yr)	56 (28-65)	69 (66-81)	< 0.001
Body weight (kg)	61.1 (35.0-97.4)	57.8 (41.0-74.8)	0.105
Body mass index (kg/m²)	22.7 (15.8-32.2)	22.9 (17.9-28.9)	0.892
Baseline HCV-RNA (log IU/mL)	6.7 (3.9-7.7)	6.7 (3.1-7.8)	0.766
White blood cell (/mm³)	5000 (1900-8720)	4500 (2700-7700)	0.245
Hemoglobin (g/dL)	14.0 (9.1-18.6)	13.5 (9.5-16.3)	0.121
Platelets (× 10⁴/mm³)	15.8 (6.5-28.7)	13.4 (8.3-29.0)	0.068
Albumin (mg/dL)	4.1 (2.7-5.9)	3.9 (2.4-4.4)	0.007
AST (IU/L)	40 (17-249)	45 (20-163)	0.909
ALT (IU/L)	48 (15-278)	38 (15-189)	0.486
γ-GTP (IU/L)	39 (11-717)	25 (11-144)	0.034
Serum creatinine (mg/dL)	0.7 (0.4-1.2)	0.8 (0.4-1.0)	0.036
Estimated GFR (mL/min)	79.0 (44.0-134.0)	71.5 (39.0-101.9)	0.006
Prior treatment response, n (naïve/relapse/non-responder)	45/26/7	15/15/4	0.403
Liver histology (F0-2/3-4/ND)	21/6/51	4/3/27	0.348
IL28B SNP (rs8099917), n (TT/non-TT/ND)	51/22/5	28/5/1	0.235
HCV ISDR, n (0/1-3 /4-/NT)	32/26/6/14	15/10/2/7	0.955
HCV Core 70, n (Wild/Mutant/ND)	46/18/14	18/10/6	0.751
HCV Core 91, n (Wild/Mutant/ND)	42/22/14	19/9/6	1
Serum CXCL10 (pg/mL)	510 (95-1794)	543 (118-1218)	0.445

GFR: Glomerular filtration rate; IL28B SNP: Interleukin-28B single nucleotide polymorphism; ND: Not determined; ISDR: Interferon sensitivity-determining region; HCV Core 70 or 91: At position 70 or 91 of the HCV core protein; CXCL10: Chemokine (C-X-C motif) ligand 10; HCV: Hepatitis C virus; AST: Aspartate transaminase; ALT: Alanine aminotransferase; γ-GTP: γ-glutamyl-transpeptidase.

Table 2 Patient characteristics by age (simeprevir)

Factors (median, range)	Patients aged < 66	Patients aged ≥ 66	P value
n	37	39	-
Gender, n (%) (male/female)	19/18 (48.6)	14/25 (64.1)	0.123
Age (yr)	59 (36-65)	71 (66-86)	< 0.001
Body weight (kg)	62.0 (39.8-94.0)	56.0 (37.5-76.6)	0.011
Body mass index (kg/m²)	22.8 (17.2-30.3)	22.7 (17.8-32.1)	0.287
Baseline HCV-RNA (log IU/mL)	6.7 (5.4-7.8)	6.6 (4.7-7.6)	0.631
White blood cells (/mm³)	4620 (2600-7800)	4300 (2400-8100)	0.010
Hemoglobin (g/dL)	13.8 (11.0-16.7)	13.1 (9.8-16.8)	< 0.001
Platelets (× 10⁴/mm³)	16.4 (8.7-28.8)	16.3 (7.3-31.7)	0.291
Albumin (mg/dL)	4.2 (2.8-4.8)	4.0 (3.1-4.6)	0.002
AST (IU/L)	45 (21-159)	34 (19-128)	0.056
ALT (IU/L)	42 (16-316)	29 (12-112)	0.006
γ-GTP (IU/L)	29 (13-260)	27 (9-171)	0.388
Serum creatinine (mg/dL)	0.70 (0.44-1.01)	0.70 (0.42-1.36)	0.689
Estimated GFR (mL/min)	78.7 (50.0-112.6)	77.4 (41.3-109.0)	0.221
Prior treatment response, n (naïve/relapse/non-responder)	20/10/7	13/16/10	0.197
Liver histology (F0-2/3-4/ND)	12/6/19	19/5/15	0.483
IL28B SNP (rs8099917), n (TT/non-TT/ND)	17/19/1	18/17/4	1
HCV ISDR, n (0/1-3/4-/ND)	9/13/5/10	11/12/2/14	0.044
HCV Core 70, n (Wild/Mutant/ND)	17/13/7	15/8/16	1
HCV Core 91, n (Wild/Mutant/ND)	18/12/7	18/5/16	0.385

GFR: Glomerular filtration rate; IL28B SNP: Interleukin-28B single nucleotide polymorphism; ND: Not determined; ISDR: Interferon sensitivity-determining region; HCV core 70 or 91: At position 70 or 91 of the HCV core protein; HCV: Hepatitis C virus; AST: Aspartate transaminase; ALT: Alanine aminotransferase; γ-GTP: γ-glutamyl-transpeptidase.

Table 3 Treatment tolerability (telaprevir)

	Patients aged < 66	Patients aged ≥ 66	P value
Initial doses (median, range)
PEG-IFN/BW (μg/kg per week)	1.48 (0.98-2.00)	1.49 (1.15-1.87)	0.859
TVR/BW (mg/kg per day)	33.0 (19.2-64.3)	29.2 (7.5-54.2)	0.044
TVR (2250 mg/1500 mg/others), n	55/23/0	11/21/2	< 0.001
RBV/BW (mg/kg per day)	11.4 (6.8-20.0)	11.4 (5.7-28.0)	0.103
Dose reduction, n (%)
PEG-IFN	7 (8.9)	6 (17.6)	0.209
TVR	19 (24.3)	12 (35.3)	0.256
RBV	40 (51.2)	27 (79.4)	0.006
Discontinuation, n (%)
PEG-IFN	13 (16.7)	4 (11.8)	0.580
TVR	12 (15.4)	9 (26.5)	0.192
RBV	12 (15.4)	7 (20.6)	0.585
Adherence, mean ± SD (%)
PEG-IFN	88.2 ± 25.7	90.1 ± 19.8	0.606
TVR	88.8 ± 22.8	83.5 ± 25.5	0.103
RBV	79.3 ± 26.2	62.7 ± 25.3	< 0.001

PEG-IFN: Pegylated interferon; BW: Bodyweight; TVR: Telaprevir; RBV: Ribavirin.

Table 4 Treatment tolerability (simeprevir)

	Patients aged < 66	Patients aged ≥ 66	P value
Initial doses (median, range)
PEG-IFNα2a (180/90) (μg/wk)	19/0	10/1	0.366
PEG-IFNα2b (120/100/80/others) (μg/wk)	2/16/5/1	0/25/5/1	0.422
SMV/BW (mg/kg per day)	1.6 (1.1-2.5)	1.8 (1.3-2.7)	0.011
RBV/BW (mg/kg per day)	11.6 (6.8-17.1)	12.3 (6.0-20.6)	0.166
Dose reduction, n (%)
PEG-IFN	5 (13.5)	6 (15.3)	1
SMV	0	0	1
RBV	3 (8.1)	6 (15.3)	0.481
Discontinuation, n (%)
PEG-IFN	5 (13.5)	5 (12.8)	1
SMV	2 (5.4)	2 (5.1)	1
RBV	11 (29.7)	23 (58.9)	0.012
Adherence, mean ± SD (%)
PEG-IFN	93.6 ± 16.8	92.3 ± 19.5	0.592
SMV	98.1 ± 7.2	93.9 ± 18.1	0.079
RBV	91.0 ± 16.1	86.8 ± 20.2	0.126

PEG-IFN: Pegylated interferon; SMV: Simeprevir; BW: Bodyweight; RBV: Ribavirin.

Table 5 Univariate and multivariate analysis of factors contributing to SVR24 (telaprevir)

Factors	Univariate analysis		Multivariate analysis
Factors	Odds ratio (95%CI)	P value	Odds ratio (95%CI)	P value
Age	1.012 (0.955-1.072)	0.689
Gender (female)	0.784 (0.262-2.342)	0.663
Body mass index (kg/m²)	1.074 (0.875-1.318)	0.495
Prior treatment response (non-NR)	3.850 (0.830-17.861)	0.085
Baseline HCV-RNA (log IU/mL)	1.264 (0.457-3.495)	0.652
Baseline ALT (IU/mL)	1.008 (0.998-1.017)	0.105
Baseline platelets (× 10⁴/mm³)	1.017 (0.906-1.142)	0.775
Baseline hemoglobin (g/dL)	1.038 (0.736-1.464)	0.830
IL28B SNP (TT)	6.700 (1.826-24.584)	0.004	8.160 (1.593-41.804)	0.012
Initial dose of TVR (2250 mg/d)	2.069 (0.670-6.553)	0.204
TVR/BW (mg/kg per day)	0.938 (0.870-1.011)	0.093
RBV/BW (mg/kg per day)	0.811 (0.617-1.066)	0.133
PEG-IFN dose reduction (none)	2.134 (0.253-17.988)	0.486
TVR dose reduction (none)	1.020 (0.281-3.703)	0.976
RBV dose reduction (none)	1.548 (0.433-5.525)	0.501
Adherence of RBV (> 60%)	6.873 (1.784-26.474)	0.005	11.052 (1.160-105.273)	0.037
RVR (none)	0.88 (0.123-1.216)	0.104

HCV: Hepatitis C virus; ALT: Alanine aminotransferase; NR: Non-responder; IL28B SNP: Interleukin-28B single nucleotide polymorphism; TVR: Telaprevir; RVR: Rapid virological response; PEG-IFN: Pegylated interferon; BW: Bodyweight; RBV: Ribavirin.

Table 6 Univariate and multivariate analysis of factors contributing to SVR24 (simeprevir)

Factors	Univariate analysis		Multivariate analysis
Factors	Odds ratio (95%CI)	P value	Odds ratio (95%CI)	P value
Age	0.998 (0.942-1.058)	0.953
Gender (female)	0.330 (0.083-1.314)	0.116
Body mass index (kg/m²)	1.164 (0.934-1.450)	0.175
Prior treatment response (non-NR)	2.955 (0.811-10.764)	0.101
Baseline HCV-RNA (log IU/mL)	0.767 (0.328-1.791)	0.540
Baseline ALT (IU/mL)	0.998 (0.985-1.012)	0.785
Baseline platelets (× 10⁴/mm³)	1.082 (0.953-1.228)	0.224
Baseline hemoglobin (g/dL)	1.257 (0.827-1.910)	0.285
IL28B SNP (TT)	12.593 (1.516-104.576)	0.019	9.677 (1.114-84.087)	0.040
SMV/BW (mg/kg per day)	0.306 (0.054-1.742)	0.182
RBV/BW (mg/kg per day)	1.085 (1.138-3.913)	0.501
PEG-IFN dose reduction (none)	7.250 (1.712-30.700)	0.007	6.557 (1.328-32.377)	0.021
RBV dose reduction (none)	1.556 (0.470-5.160)	0.470
RVR (none)	0.351 (0.075-1.637)	0.183

HCV: Hepatitis C virus; ALT: Alanine aminotransferase; NR: Non-responder; IL28B SNP: Interleukin-28B single nucleotide polymorphism; SMV: Simeprevir; BW: Bodyweight; PEG-IFN: Pegylated interferon; RBV: Ribavirin; RVR: Rapid virological response.

Citation: Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. World J Hepatol 2017; 9(5): 252-262
URL: https://www.wjgnet.com/1948-5182/full/v9/i5/252.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i5.252